Swiss National Bank Allovir, Inc. Transaction History

Swiss National Bank

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	SELL	$2.15 - $3.64 $24,510 - $41,496	-11,400 Reduced 9.22%	112,300 $241,000
Q2 2023 Aug 09, 2023	BUY	$3.17 - $5.82 $73,227 - $134,442	23,100 Added 22.96%	123,700 $420,000
Q1 2023 May 10, 2023	SELL	$3.94 - $7.05 $46,098 - $82,485	-11,700 Reduced 10.42%	100,600 $396,000
Q4 2022 Feb 08, 2023	BUY	$4.7 - $9.98 $13,630 - $28,942	2,900 Added 2.65%	112,300 $576,000
Q3 2022 Nov 09, 2022	BUY	$4.13 - $8.79 $133,812 - $284,796	32,400 Added 42.08%	109,400 $863,000
Q2 2022 Aug 09, 2022	SELL	$3.26 - $7.06 $25,428 - $55,068	-7,800 Reduced 9.2%	77,000 $300,000
Q1 2022 May 09, 2022	BUY	$6.75 - $13.52 $39,825 - $79,768	5,900 Added 7.48%	84,800 $572,000
Q2 2021 Aug 06, 2021	BUY	$19.44 - $25.06 $962,280 - $1.24 Million	49,500 Added 168.37%	78,900 $1.56 Million
Q4 2020 Feb 05, 2021	BUY	$23.94 - $46.81 $703,836 - $1.38 Million	29,400 New	29,400 $1.13 Million

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $40.9M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.